JP2018048151A5 - - Google Patents

Download PDF

Info

Publication number
JP2018048151A5
JP2018048151A5 JP2017192907A JP2017192907A JP2018048151A5 JP 2018048151 A5 JP2018048151 A5 JP 2018048151A5 JP 2017192907 A JP2017192907 A JP 2017192907A JP 2017192907 A JP2017192907 A JP 2017192907A JP 2018048151 A5 JP2018048151 A5 JP 2018048151A5
Authority
JP
Japan
Prior art keywords
inhibitor
cancer stem
brain tumor
pharmaceutical composition
stem cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017192907A
Other languages
English (en)
Japanese (ja)
Other versions
JP6618968B2 (ja
JP2018048151A (ja
Filing date
Publication date
Priority claimed from EP10185930A external-priority patent/EP2446895A1/en
Application filed filed Critical
Publication of JP2018048151A publication Critical patent/JP2018048151A/ja
Publication of JP2018048151A5 publication Critical patent/JP2018048151A5/ja
Application granted granted Critical
Publication of JP6618968B2 publication Critical patent/JP6618968B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017192907A 2010-10-01 2017-10-02 腫瘍幹細胞におけるeph受容体発現 Active JP6618968B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10185930A EP2446895A1 (en) 2010-10-01 2010-10-01 EPH receptor expression in tumor stem cells
EP10185930.4 2010-10-01

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2015200808A Division JP6523910B2 (ja) 2010-10-01 2015-10-09 腫瘍幹細胞におけるeph受容体発現

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019205190A Division JP2020037579A (ja) 2010-10-01 2019-11-13 腫瘍幹細胞におけるeph受容体発現

Publications (3)

Publication Number Publication Date
JP2018048151A JP2018048151A (ja) 2018-03-29
JP2018048151A5 true JP2018048151A5 (cg-RX-API-DMAC7.html) 2018-05-17
JP6618968B2 JP6618968B2 (ja) 2019-12-11

Family

ID=43856109

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2013530753A Pending JP2013540117A (ja) 2010-10-01 2011-09-30 腫瘍幹細胞におけるeph受容体発現
JP2015200808A Active JP6523910B2 (ja) 2010-10-01 2015-10-09 腫瘍幹細胞におけるeph受容体発現
JP2017192907A Active JP6618968B2 (ja) 2010-10-01 2017-10-02 腫瘍幹細胞におけるeph受容体発現
JP2019205190A Pending JP2020037579A (ja) 2010-10-01 2019-11-13 腫瘍幹細胞におけるeph受容体発現

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2013530753A Pending JP2013540117A (ja) 2010-10-01 2011-09-30 腫瘍幹細胞におけるeph受容体発現
JP2015200808A Active JP6523910B2 (ja) 2010-10-01 2015-10-09 腫瘍幹細胞におけるeph受容体発現

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019205190A Pending JP2020037579A (ja) 2010-10-01 2019-11-13 腫瘍幹細胞におけるeph受容体発現

Country Status (11)

Country Link
US (1) US9078857B2 (cg-RX-API-DMAC7.html)
EP (2) EP2446895A1 (cg-RX-API-DMAC7.html)
JP (4) JP2013540117A (cg-RX-API-DMAC7.html)
KR (2) KR101719966B1 (cg-RX-API-DMAC7.html)
AU (1) AU2011310109B2 (cg-RX-API-DMAC7.html)
CA (1) CA2813101C (cg-RX-API-DMAC7.html)
DK (1) DK2621513T3 (cg-RX-API-DMAC7.html)
ES (1) ES2616444T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ609594A (cg-RX-API-DMAC7.html)
PL (1) PL2621513T3 (cg-RX-API-DMAC7.html)
WO (1) WO2012042021A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140031175A (ko) 2010-12-08 2014-03-12 스템 센트알엑스 인코포레이티드 신규 조절제 및 용법
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
EP2733206A1 (en) * 2012-11-19 2014-05-21 Naroa LLC Method for the isolation for mammalian stem cells using EphA2 and uses thereof
BR112016010051A2 (pt) 2013-11-04 2017-12-05 Pfizer ?conjugados de anticorpo-fármaco anti-efna4?
EP3137114B8 (en) 2014-04-30 2021-08-04 Pfizer Inc. Anti-ptk7 antibody-drug conjugates
KR102674191B1 (ko) 2014-12-10 2024-06-11 하이퍼스템 에스에이 뇌암 줄기 세포의 성장, 이동 및 침습성 감소 그리고 뇌종양을 가진 환자의 생존 개선 방법 및 조성물
US10783439B2 (en) * 2015-05-08 2020-09-22 FlowJo, LLC Plugin interface and framework for integrating a remote server with sample data analysis software
EP3373939A4 (en) 2015-11-10 2019-06-26 B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University MEDIUM AND METHOD FOR REDUCING TUMORIGENITY OF CANCER STEM CELLS
JP7680047B2 (ja) * 2020-03-31 2025-05-20 慶應義塾 ゲノム編集多能性幹細胞を用いた治療薬

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050281783A1 (en) * 2003-10-15 2005-12-22 Kinch Michael S Listeria-based EphA2 vaccines
EP1778726A4 (en) * 2004-08-16 2009-03-18 Medimmune Inc INTEGRIN ANTAGONISTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-ASSAYED CYTOTOXICITY ACTIVITY
US20070248628A1 (en) * 2005-12-06 2007-10-25 Keller Lorraine H Immunogens in cancer stem cells
US8343461B2 (en) * 2006-03-08 2013-01-01 Wake Forest University Health Sciences Molecular signature of cancer
RU2525133C2 (ru) * 2007-08-30 2014-08-10 Дайити Санкио Компани, Лимитед Антитело к epha2

Similar Documents

Publication Publication Date Title
JP2018048151A5 (cg-RX-API-DMAC7.html)
JP5902138B2 (ja) 癌治療と幹細胞調節のための方法
MX2024010140A (es) Nuevos metodos.
MY199967A (en) Combinations of lsd1 inhibitors for use in the treatment of solid tumors
AR060150A1 (es) Heteropentaciclos activos como inhibidores de quinasas, y su uso para tratar trastornos de la proliferacion celular
JP2015520753A5 (cg-RX-API-DMAC7.html)
JP2019516754A5 (cg-RX-API-DMAC7.html)
RU2018109902A (ru) Виды комбинированной терапии для лечения рака
JP2019519519A5 (cg-RX-API-DMAC7.html)
JP2016501013A5 (cg-RX-API-DMAC7.html)
MX354210B (es) Formas farmaceuticas orales de liberacion controlada de farmacos escasamente solubles y los usos de estas.
WO2007055941A3 (en) Histone deacetylase inhibitors with aryl-pyrazolyl motifs
WO2016145234A3 (en) Use of mk2 inhibitor peptide-containing compositions for treating non-small cell lung cancer with same
Ding et al. Overexpression of miR-582-5p inhibits the apoptosis of neuronal cells after cerebral ischemic stroke through regulating PAR-1/Rho/Rho axis
RU2015140572A (ru) Способы лечения колоректального рака
CN110062628A (zh) 一种瑞卡帕布口服缓控释药物组合物及其用途
WO2018175323A4 (en) Gemcitabine derivatives for cancer therapy
JP2013507954A5 (cg-RX-API-DMAC7.html)
Pullamsetti et al. From cancer biology to new pulmonary arterial hypertension therapeutics: targeting cell growth and proliferation signaling hubs
Wang et al. Gene therapy for vein graft failure
JP2017516832A5 (cg-RX-API-DMAC7.html)
WO2005028617A3 (en) Antisense inhibition of laminin-8 expression to inhibit human gliomas
Desmarais et al. Infiltration of F98 glioma cells in Fischer rat brain is temporary stimulated by radiation
MX2023002416A (es) Compuestos, composiciones y metodos para la inhibicion de la desmetilasa de histona lisina.
CN105232507B (zh) Gw3965作为parp1抑制剂的应用